Get the Stockscreener App
0.4051
1.76%
0.007
After Hours:
.40
-0.0051
-1.26%
Theriva Biologics Inc stock is traded at $0.4051, with a volume of 156.46K.
It is up +1.76% in the last 24 hours and down -1.20% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.3981
Open:
$0.3996
24h Volume:
156.46K
Relative Volume:
0.33
Market Cap:
$3.89M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.3492
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
+1.68%
1M Performance:
-1.20%
6M Performance:
-63.17%
1Y Performance:
-70.64%
1-Day Range:
$0.3879
$0.4051
1-Week Range:
$0.3811
$0.41
52-Week Range:
$0.3654
$2.64
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.4051 | 3.82M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Theriva Biologics Inc Stock (TOVX) Latest News
How interest rate cuts could boost Theriva Biologics Inc. stockPortfolio Return Report & Entry and Exit Point Strategies - newser.com
Is Theriva Biologics Inc. (SFY0) stock a defensive play amid uncertaintyAnalyst Upgrade & Scalable Portfolio Growth Methods - newser.com
Is Theriva Biologics Inc. (SFY0) stock cheap by valuation metrics2025 Sector Review & Safe Entry Zone Tips - newser.com
What downside risks could hit Theriva Biologics Inc. stockMarket Risk Analysis & Low Volatility Stock Suggestions - newser.com
Is it time to cut losses on Theriva Biologics Inc.Earnings Overview Summary & Fast Momentum Stock Entry Tips - newser.com
Will Theriva Biologics Inc. stock remain on Wall Street radarMarket Weekly Review & Daily Entry Point Alerts - newser.com
How Theriva Biologics Inc. stock performs after earnings2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Published on: 2025-09-29 13:52:37 - newser.com
Should you hold or exit Theriva Biologics Inc. nowPortfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Why retail investors favor Theriva Biologics Inc. stockQuarterly Growth Report & Free Safe Capital Growth Stock Tips - newser.com
Is Theriva Biologics Inc. stock attractive post correctionCPI Data & Community Consensus Stock Picks - newser.com
Visual analytics tools that track Theriva Biologics Inc. performanceJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - newser.com
Is this a good reentry point in Theriva Biologics Inc.2025 EndofYear Setup & Low Risk High Reward Ideas - newser.com
Published on: 2025-09-29 03:59:06 - newser.com
What analysts say about Theriva Biologics Inc SFY0 stockPrice Action Trading & Low Risk High Yield - earlytimes.in
What analysts say about Theriva Biologics Inc stockFibonacci Retracement Levels & Machine Learning Stock Picks, Daily - earlytimes.in
Theriva Biologics Inc Stock Analysis and ForecastInsider Trading Compliance & Small Capital Portfolio - earlytimes.in
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Cap:
|
Volume (24h):